Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
2022 · Frontiers in Oncology · 5 citations
https://doi.org/10.3389/fonc.2022.1081750
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
10
Papers
131
Citations
4
h-index
2
i10-index
Li Liao is an academic researcher from Guangxi Medical University. The author has contributed to research in topics: Dementia and Cognitive Impairment Research & Asthma and respiratory diseases & Cancer Immunotherapy and Biomarkers. The author has an h-index of 4, co-authored 9 publications.
ORCID: 0009-0003-3563-1128Click to start Chat